HNRNPU K181 Lactylation Rewires Serine Metabolism in Cervical Cancer

Study Background and Research Question

Cervical cancer remains a major global health challenge, ranking as the fourth most common malignancy among women worldwide. Despite advances in diagnosis and treatment, the molecular mechanisms underlying cervical cancer progression and its characteristic metabolic reprogramming are not fully elucidated. Tumor cells exhibit increased glycolytic flux (the Warburg effect), leading to lactate accumulation, which has recently been recognized not only as a metabolic byproduct, but also as a modulator of cell signaling via post-translational protein modifications such as lysine lactylation. While histone lactylation has been implicated in gene regulation and cell fate decisions, the functional consequences of non-histone protein lactylation in cancer biology have remained largely unexplored. The reference study addresses whether lactylation of the RNA-binding protein HNRNPU at lysine 181 drives metabolic rewiring and tumor growth in cervical cancer by regulating serine biosynthesis.

Key Innovation from the Reference Study

The central innovation of this research lies in identifying HNRNPU as a novel non-histone substrate of lysine lactylation, directly linking lactate metabolism to post-transcriptional regulation of serine biosynthesis in cervical cancer. Specifically, the study demonstrates that lactylation at K181 stabilizes HNRNPU and enhances its binding to PHGDH mRNA, which is pivotal for the serine synthesis pathway. Furthermore, the research reveals a competitive modification switch at K181 between lactylation and NAA50-mediated acetylation, highlighting a dynamic regulatory mechanism for HNRNPU function. This work is among the first to show that post-translational modification of a splicing factor by lactylation can govern metabolic gene expression and tumor cell proliferation, positioning protein lactylation as a promising target for therapeutic intervention in malignancies characterized by metabolic reprogramming.

Methods and Experimental Design Insights

The investigators employed a multi-faceted experimental strategy integrating bioinformatics, proteomics, molecular biology, and in vivo cancer models. Key elements of their approach included:

• Transcriptomic analysis using the TCGA-CESC cohort and proteomic datasets (PRIDE PXD055203) to identify differential expression of splicing factors in cervical cancer versus normal tissue.
• Mass spectrometry-based identification of lactylated proteins, confirming HNRNPU K181 lactylation in tumor samples.
• Site-directed mutagenesis and immunoprecipitation assays to dissect the functional effects of K181 lactylation and acetylation on HNRNPU stability and binding activity.
• RNA immunoprecipitation and qPCR to assess the impact on PHGDH mRNA stability and isoform expression.
• Cell proliferation and metabolic flux assays to determine the biological consequences of HNRNPU modifications in vitro.
• Xenograft mouse models and pharmacological inhibition experiments (using Pazopanib) to evaluate the translational relevance of the findings in vivo.

Protocol Parameters

• Cell line selection: Use cervical cancer cell lines exhibiting elevated glycolytic activity to model lactate accumulation and HNRNPU expression.
• Lactylation detection: Employ anti-lactyllysine antibodies for immunoblotting and immunoprecipitation, validated by mass spectrometry for site-specific modification (e.g., K181).
• RNA immunoprecipitation: Optimize lysis and antibody incubation conditions to preserve RNA-protein interactions for downstream qPCR analysis of PHGDH transcripts.
• In vivo modeling: For xenograft studies, inject modified cervical cancer cells into immunodeficient mice and monitor tumor growth after pharmacological intervention (e.g., Pazopanib administration).

Core Findings and Why They Matter

The study’s principal findings are as follows:

• HNRNPU is highly expressed in cervical cancer tissues compared to normal controls at the protein level, despite no significant mRNA upregulation, indicating post-transcriptional or post-translational regulation (reference).
• Lysine 181 lactylation stabilizes HNRNPU and enhances its interaction with PHGDH mRNA, specifically promoting the exon 1-containing transcript variant that is necessary for robust PHGDH protein expression and serine synthesis.
• Metabolic rewiring via HNRNPU K181 lactylation leads to increased serine biosynthesis, supporting redox balance, nucleotide production, and rapid cell proliferation in cervical cancer models.
• Acetylation at K181, mediated by NAA50, antagonizes lactylation, establishing a dynamic PTM switch that fine-tunes HNRNPU’s regulatory role.
• Pharmacological inhibition of HNRNPU K181 lactylation (using Pazopanib) suppresses PHGDH expression and tumor growth in vivo, highlighting the therapeutic potential of targeting this axis.

These findings collectively position lactylation of non-histone proteins as a key mechanism by which cancer cells couple metabolic state with the regulation of gene expression, specifically impacting the serine synthesis pathway that is crucial for tumor progression.

Comparison with Existing Internal Articles

No direct internal articles are available for comparison. However, the mechanistic insights provided by this study complement broader themes in cancer metabolism research—particularly the growing recognition that post-translational protein modifications serve as integrators of metabolic and transcriptional changes. For researchers developing cell-based assay proteasome controls or exploring ubiquitin-proteasome system research, these findings underscore the importance of distinguishing on-target effects of metabolic interventions from off-target or nonspecific outcomes.

Limitations and Transferability

Several limitations should be considered:

• While the study thoroughly characterizes HNRNPU K181 lactylation in cervical cancer, the transferability of these findings to other cancer types or primary patient samples remains to be systematically evaluated.
• The use of pharmacologic inhibitors such as Pazopanib, which can have pleiotropic effects, warrants further investigation to confirm specificity for the HNRNPU-PHGDH axis.
• Potential compensatory mechanisms or redundancy among splicing factors and metabolic pathways could limit the efficacy of targeting a single post-translational modification.

Despite these limitations, the study provides a robust framework for investigating how metabolic state and RNA processing intersect to drive malignancy, with clear implications for the design of future mechanistic studies of proteasome or metabolic regulation across cancer types.

Research Support Resources

To facilitate proteasome inhibition validation and serve as a rigorous negative control in mechanistic studies of the ubiquitin-proteasome system, researchers may consider using (R)-MG132 (SKU C3348), a functionally inactive MG-132 enantiomer available from APExBIO. This compound is particularly suited for cell-based assay proteasome control experiments, helping to distinguish true on-target proteasome inhibition from off-target effects. Utilizing such stereoisomeric control reagents strengthens the interpretability and reproducibility of studies examining post-translational modifications and metabolic rewiring in cancer models.